Skip to main content
SpringerLink
Log in

Is There A Role For Pharmacoeconomics In Developing Countries?

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Singer ME. Developing nations special issue. Pharmacoeconomics 2009; 27 (11): 887–9

    Article  PubMed  Google Scholar 

  2. Babigumira JB, Sethi AK, Smyth KA, et al. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 2009; 27 (11): 963–73

    Article  PubMed  Google Scholar 

  3. WHO. WHO operational package for assessing, monitoring and evaluating country pharmaceutical situations: guide for coordinators and data collectors [WHO/TCM/2007.2]. Geneva: WHO, 2007 Dec [online]. Available from URL: (http://apps.who.int/medicinedocs/documents/s14877e/s14877e.pdf) [Accessed 2010 Aug 29]

    Google Scholar 

  4. Yang B-M. The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics 2009; 27 (11): 891–901

    Article  PubMed  Google Scholar 

  5. How to develop and implement a national drug policy. 2nd ed. Geneva: WHO, 2001 [online]. Available from URL: (http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf) [Accessed 2010 Aug 28]

    Google Scholar 

  6. Oortwijn W, Mathijssen J, Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy 2010; 95: 174–84

    Article  PubMed  Google Scholar 

  7. The World Bank. GNI per capita, Atlas method (current US$) [online]. Available from URL: (http://data.worldbank.org/indicator/NY.GNP.PCAP.CD) [Accessed 2010 Aug 26]

  8. WHO. The world medicines situation [WHO/EDM/PAR/2004.5]. Geneva: WHO, 2004 [online]. Available from URL: (http://www.searo.who.int/LinkFiles/Reports_World_Medicines_Situation.pdf) [Accessed 2010 Aug 19]

    Google Scholar 

  9. The World Bank. Health expenditure per capita (current US$) [online]. Available from URL: (http://data.worldbank.org/indicator/SH.XPD.PCAP) [Accessed 2010 Aug 22]

  10. Taiwan: Hutchinson country facts [online]. Available from URL: (http://www.talktalk.co.uk/reference/encyclopaedia/countryfacts/taiwan.html) [Accessed 2010 Jul 7]

  11. Leung GM, Wagstaff A, Lindelow M, et al. The health systems of China, Hong Kong and Taiwan. In: Heggenhougen K, Quah S, editors. International encyclopedia of public health. San Diego (CA): Academic Press, 2008: 656–71

    Chapter  Google Scholar 

  12. Kima HJ, Chungb W, Lee SG. Lessons from Korea’s pharmaceutical policy reform: the separation of medical institutions and pharmacies for outpatient care. Health Policy 2004 June; 68 (3): 267–75

    Google Scholar 

  13. Chou YJ, Yip WC, Lee CH, et al. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan’s experience. Health Policy Plann 2003; 18 (3): 316–29

    Article  CAS  Google Scholar 

  14. Laing R. Health and pharmacy systems in developing countries. 2001 Apr 9 [online]. Available from URL: (http://www.wto.org/english/tratop_e/trips_e/hosbjor_presentations_e/05laing_e.pdf) [Accessed 2001 Apr 9]

    Google Scholar 

  15. Kwon S. Pharmaceutical reform and physician strikes in Korea: separation of drug prescribing and dispensing. SocSci Med 2003 Aug; 57 (3): 529–38

    Google Scholar 

  16. Tarn TY-H. Case of Taiwan HTA. Presentation at the 3rd Asia-Pacific ISPOR Conference; 2008 Sep 7-9; Seoul

    Google Scholar 

  17. Kim C. Health technology assessment in South Korea. Int J Technol Assess Health Care 2009; 25 (Suppl. 1): 219–23

    Article  PubMed  Google Scholar 

  18. Babar ZU, Ibrahim M, Izham M, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 2007; 4 (3): 466–75

    Article  Google Scholar 

  19. WHO, Health Action International. Medicine prices: a new approach to measurement. 2003 ed. [working draft for field testing and revision]. Geneva: WHO, 2003 [online]. Available from URL: (http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.2.pdf) [Accessed 2010 Aug 28]

    Google Scholar 

  20. Cheraghali AM. Pharmacoeconomics: an effective tool for prioritization in Iran healthcare system. Iranian J Pharmaceutical Res 2008; 7 (2): 89–91 [online]. Available from URL: (http://www.ijpr-online.com/docs/20082/IJPR606.pdf) [Accessed 2010 Aug 27]

    Google Scholar 

  21. Dinarvand R. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines. Iranian J Publ Health 2009; 38 Suppl.1: 158–61 [online]. Available from URL: (http://journals.tums.ac.ir/upload_files/pdf/13390.pdf) [Accessed 2010 Aug 29]

    Google Scholar 

  22. Cheraghali AM. Iran pharmaceutical market. Iranian J Pharmaceutical Res 2006; 1: 1-7 [online]. Available from URL: (http://www.sid.ir/en/VEWSSID/J_pdf/92720060110.pdf) [Accessed 2010 Aug 29 ]

    Google Scholar 

  23. Iranian National Society of PharmEconomics [online]. Available from URL: (http://pharmeconomics.com/) [Accessed 2010 Jul 29]

  24. Iran, medicine prices, affordability and availability. Amsterdam: Health Action International, 2010. (Data on file)

  25. Sultan MSA. How to integrate pharmacoeconomic data in the Middle East countries: the status in Saudi Arabia. Pharmacoeconomics Meeting, Servier International; 2008 Jan 24; Cairo

    Google Scholar 

  26. University Sains Malaysia. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Pharmacoeconomics, Undergraduate course. Penang [online]. Available from URL: (http://www.usm.my/dsap/undergrad.asp) [Accessed 2010 Aug 24]

  27. Health Action International. Medicine prices, availability, affordability and price components [online]. Available from URL: (http://www.haiweb.org/medicineprices/survey_results.php) [Accessed 2010 Aug 29]

  28. Kingdom of Saudi Arabia. Saudi Food and Drug Authority [online]. Available from URL: (http://www.sfda.gov.sa/En/Drug/Topics/Human_Drugs.htm) [Accessed 2010 Aug 23]

  29. Hameed A. Pharmacoeconomics and outcome research in Pakistan [online]. Available from URL: (http://www.ispor.org/conferences/shanghai0306/pdf/07-Pakistan-Hameed.pdf) [Accessed 2010 Aug 20]

  30. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Brief definition [online]. Available from URL: (http://www.ispor.org/terminology/default.asp) [Accessed 2010 Sep 20]

  31. The Network for Consumer Protection. Prices, availability and affordability of medicines in Pakistan. Islamabad: The Network for Consumer Protection, 2006 [online]. Available from URL: (http://www.haiweb.org/medicineprices/surveys/200407PK/survey_report.pdf) [Accessed 2010 Aug 19]

    Google Scholar 

  32. WHO, Health Action International. Indonesia: medicine prices, availability and affordability [online]. Available from URL: (http://www.haiweb.org/medicineprices/surveys/200408ID/sdocs/Indonesia-summary-report-FINAL.pdf) [Accessed 2010 Jul 23]

  33. Sooksriwong C, Yoongthong W, Suwattanapreeda S, et al. Medicine prices in Thailand: a result of no medicine pricing policy. Southern Med Review 2009; 2 (2): 10–14 [online]. Available from URL: (http://apps.who.int/medicinedocs/index/assoc/s16381e/s16381e.pdf) [Accessed 2010 Jul 27]

    Google Scholar 

  34. WHO, Health Action International. Philippines: public procurement prices of medicines [online]. Available from URL: (http://www.haiweb.org/medicineprices/surveys/200807PHB/sdocs/zPhilippines-procurement-Final.pdf) [Accessed 2010 Aug 22]

  35. International Health Economics Association (iHEA). Chulalongkorn University: introduction to pharmacoeconomics [online]. Available from URL: (http://www.healtheconomics.org/education/2004/06/chulalongkorn-universityintroducti.html) [Accessed 2010 Aug 26]

Download references

Acknowledgements

No sources of funding were used to prepare this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Mail Bag 92019, Auckland, 1142, New Zealand

    Zaheer-Ud-Din Babar & Shane Scahill

Authors
  1. Zaheer-Ud-Din Babar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shane Scahill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zaheer-Ud-Din Babar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Babar, ZUD., Scahill, S. Is There A Role For Pharmacoeconomics In Developing Countries?. Pharmacoeconomics 28, 1069–1074 (2010). https://doi.org/10.2165/11584890-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11584890-000000000-00000

Keywords

Search

Navigation